Evaluation of the effect of vitamin D supplementation in reducing vertigo attacks and severity in Meniere’s patients, A Randomized Double-Blind Clinical Trial with Placebo-Controlled

Tehran University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新: 2023年11月13日

适应症

试验速览

暂无简介。

•Patients with a definitive diagnosis of MD according to the guidelines of the American Academy of Otolaryngology (AAO-HNS) (= 2 episodes of spontaneous vertigo, each lasting at least 20 minutes to 12 hours, along with an audiometric test that Indicates sensorineural hearing loss in the ear involved in low frequency and clinical symptoms such as tinnitus, feeling of fullness of the ear)
•Age over 18 years
•Serum levels of 25 (OH) vitD3 less than 30 ng / ml and more than 10 ng / ml

•Serum levels of 25 (OH) vitD3 less than 10 ng / ml
•Consumption of drugs that affect absorption and metabolism of vitamin D (such as: carbamazepine, phenytoin, phenobarbital, rifampin, glucocorticoids, hormonal compounds such as ocp, Bile acid sequestrants, sevelamer, orlistat ...)
•History of liver disease (chronic liver disease), kidney (chronic renal failure with GFR ? 60 ml / min with persistent increase in parathyroid hormone), uncontrolled hypothyroidism, cystic fibrosis, primary hyperparathyroidism
•History of neurological disorders
•History of other autologous diseases
•Patients with otitis media
•Having chronic metabolic disorders that may affect vitamin D levels (malabsorption, gastrointestinal surgery, celiac disease, inflammatory bowel disease (IBD)).
•Pregnant, breastfeeding
•Reluctance to continue the project, at any time and for any reason during the study
•Serious side effects during treatment

发起方